Cancer News and Research

Latest Cancer News and Research

Lymphocyte count serves as simple and effective prognostic indicator in renal cell carcinoma

Each year, kidney cancer is diagnosed in nearly 60,000 people in the U.S. Many of these patients undergo surgery to remove the affected kidney, but this procedure can be risky for the elderly and those who have other health problems. Unfortunately, the prognosis of kidney cancer patients often cannot be determined until tumor samples are surgically removed and evaluated.

2 Jun 2011

Researchers discover overactive genes that drive triple-negative breast cancer cells

Scientists at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors, a typically aggressive cancer that is highly resistant to current therapies.

2 Jun 2011

UV-screening sunglasses, contact lenses can protect eyes from aging and disease

Most of us know that UV-blocking sunscreen protects the skin from aging and disease but we don't realize that UV-screening sunglasses and contact lenses can protect eyes from aging and disease, according to a national American Optometric Association survey.

2 Jun 2011

PCF funds 14 new Creativity Awards for advanced prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.

2 Jun 2011

Adipose-derived stem cell procedure restores skull defects after brain surgery

Stem cells derived from abdominal fat—used along with a synthetic bone grafting material—are a potentially valuable new approach to repairing skull defects after brain surgery, according to a study in the June issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

2 Jun 2011

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.

2 Jun 2011

XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

On May 29, 2011 XTL has announced that its rHuEPO drug which is currently in preparations for phase 2 clinical trial, has been granted an Orphan-drug designation by the US Food and Drug Administration (FDA) for treatment of Multiple Myeloma blood cancer.

2 Jun 2011

IMRT cuts GI side effects from prostate cancer in half vs. 3D-CRT

Intensity modulated radiation therapy, a newer, more precise form of radiation therapy, causes fewer gastrointestinal side effects when combined with hormone therapy than using three-dimensional radiation therapy, according to a study published in the June issue of the International Journal of Radiation Oncology·Biology·Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO).

1 Jun 2011

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Adaptimmune announced that it has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy.

1 Jun 2011

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Preliminary results of a Phase II single-arm study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's lenvatinib demonstrated an Objective Response Rate of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer.

1 Jun 2011

HHS announces new steps to decrease premiums and help insure more Americans

The U.S. Department of Health and Human Services today announced new steps to reduce premiums and make it easier for Americans to enroll in the Pre-Existing Condition Insurance Plan. Premiums for the Federally-administered Pre-Existing Condition Insurance Plan will drop as much as 40 percent in 18 States, and eligibility standards will be eased in 23 States and the District of Columbia to ensure more Americans with pre-existing conditions have access to affordable health insurance.

1 Jun 2011

EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinoma

Pfizer Inc. announced today that the European Medicines Agency has accepted Pfizer's filing for regulatory review of axitinib for patients with advanced renal cell carcinoma after failure of prior systemic treatment.

1 Jun 2011

GE Healthcare launches global competition to raise awareness about cancer prevention

Today GE Healthcare launched a global competition on Twitter to raise public awareness about cancer prevention and healthy living.

1 Jun 2011

Twelve interventional live cases to use Toshiba's Infinix DP-i X-ray system at NCVH conference

Enabling physicians to perform a range of interventional procedures, Toshiba America Medical Systems, Inc.'s InfinixTM DP-i X-ray system provides clinicians with the ability to transition between cardiac and peripheral work seamlessly.

1 Jun 2011

Scientists find no link between XMRV retrovirus and human disease

Delineation of the origin of the retrovirus known as XMRV from the genomes of laboratory mice indicates that the virus is unlikely to be responsible for either prostate cancer or chronic fatigue syndrome in humans, as has been widely published.

1 Jun 2011

Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011

Symphogen announced today that the company will present preliminary Phase 1 data evaluating the company's lead cancer compound, Sym004, at the 2011 Annual Meeting of the American Society of Clinical Oncology in Chicago.

1 Jun 2011

CTI regains compliance with all applicable NASDAQ listing standards

Cell Therapeutics, Inc. announced that it has received a letter from The NASDAQ Stock Market LLC, indicating that CTI has regained compliance with the minimum bid price rule (i.e., NASDAQ Listing Rule 5550(a)(2)) for continued listing on The NASDAQ Capital Market and that CTI is in compliance with all applicable listing standards.

1 Jun 2011

SGO's Clinical Document outlines expert recommendations for gynecologic cancer surveillance

Although gynecologic cancers account for only 10 percent of all new cancer cases in women, these cancers account for 20 percent of all female cancer survivors. Because long-term survival is now more common, it is increasingly important to detect recurrence.

1 Jun 2011

New genetic test can predict clinical outcomes in glioblastoma patients

New research proves that a change in a particular gene can identify which patients with a specific kind of brain cancer will respond better to treatment. Testing for the gene can distinguish patients with a more- or less-aggressive form of glioblastoma, the most common and an often-fatal type of primary brain cancer, and help guide therapy, the researchers say.

1 Jun 2011

Lymphoma vaccine extends disease-free survival by 14 months

A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology.

1 Jun 2011

Cancer News and Research

Latest Cancer News and Research

Lymphocyte count serves as simple and effective prognostic indicator in renal cell carcinoma

Researchers discover overactive genes that drive triple-negative breast cancer cells

UV-screening sunglasses, contact lenses can protect eyes from aging and disease

PCF funds 14 new Creativity Awards for advanced prostate cancer research

Adipose-derived stem cell procedure restores skull defects after brain surgery

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

IMRT cuts GI side effects from prostate cancer in half vs. 3D-CRT

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

HHS announces new steps to decrease premiums and help insure more Americans

EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinoma

GE Healthcare launches global competition to raise awareness about cancer prevention

Twelve interventional live cases to use Toshiba's Infinix DP-i X-ray system at NCVH conference

Scientists find no link between XMRV retrovirus and human disease

Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011

CTI regains compliance with all applicable NASDAQ listing standards

SGO's Clinical Document outlines expert recommendations for gynecologic cancer surveillance

New genetic test can predict clinical outcomes in glioblastoma patients

Lymphoma vaccine extends disease-free survival by 14 months

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in